Shukra Pharma wins rights to distribute Wockhardt advanced anti-infective formulations across India
New Delhi:Wockhardt,a global pharma company,has authorisedShukra Pharma to represent, distribute, and manage its products across all ESIC/ESIS Hospitals, Defence Hospitals / AFMSD / DGAFMS units across India. On Wednesday, Shukra Pharmaceuticals said that it entered into a strategic non-exclusive Pan-India distribution arrangement with Wockhardt Ltd. According to an exchange filing, the authorization is effective from September 9, 2025 and is valid until March 2026. The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin), which are breakthrough antibiotics developed to combat critical infections.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!